Ron Lord, MD
Ophthalmology · St. George, UTNPI 1790991107
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,775 of the $61,347 with a category attached, or 68.1%. Bausch & Lomb Americas Inc. accounts for 65.2% of it on its own, with 18 other manufacturers making up the rest. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $533.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$40K
- Glaukos Corporation$16K
- AbbVie$2K
- Regeneron Healthcare Solutions, Inc.$932
- Genentech USA, Inc.$484
- Alcon$416
- plus $1K from 13 others
What the payments were for
- Consulting fees$16,33327%
- Speaking & faculty fees$41,77568%
- Travel & lodging$4161%
- Food & beverage$2,8235%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 3 | $40,000 |
| Glaukos Corporation | 6 | $16,365 |
| AbbVie(2 entities) | 21 | $1,923 |
| Regeneron Healthcare Solutions, Inc. | 25 | $932 |
| Genentech USA, Inc. | 23 | $484 |
| Alcon | 1 | $416 |
| Carl Zeiss Meditec, Inc. | 2 | $392 |
| Apellis Pharmaceuticals, Inc. | 7 | $213 |
| Astellas Pharma US Inc | 6 | $129 |
| Novartis | 3 | $129 |
| Eyepoint US, Inc. | 6 | $108 |
| Alimera Sciences, Inc. | 3 | $52 |
| Genentech, Inc. | 2 | $42 |
| Coherus Oncology, Inc. | 2 | $35 |
| Optos, Inc. | 1 | $33 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Dutch Ophthalmic, USA | 1 | $25 |
| Spark Therapeutics, Inc. | 1 | $23 |
| Harrow Eye, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Infinite$9,750
- Travoprost Intraocular Implant - iDose$3,333
- OZURDEX$1,614
- DAILIES$416
- CIRRUS HD-OCT$275
- CLARUS$275
- EYLEA$232
- EYLEA HD$125
- OPMI Lumera$117
- VABYSMO$115
How this compares
$61,347 in reported general payments places this provider in the 95th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 424 | $12,532 |
| Ofloxacin | 152 | $1,796 |
| Timolol Maleate | 131 | $1,034 |
| Latanoprost | 51 | $674 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 43 | $597 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $407 |
| Brimonidine Tartrate | 50 | $200 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in St. George
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Phillip HoopesDraper$26K
- Sharon RichensSt George$26K
- Douglas MarxSalt Lake City$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.